Scinai Expands CDMO Footprint with Recipharm Israel Acquisition

Event summary

  • Scinai Immunotherapeutics Ltd. acquired 100% of Recipharm Israel Ltd., expanding its CDMO capabilities.
  • The deal includes a strategic commercial collaboration with Recipharm, enabling end-to-end development and manufacturing services.
  • The Yavne facility adds 900 square meters of manufacturing space, supporting small-molecule programs and complex materials.
  • The collaboration aims to streamline transitions from early-stage to late-stage clinical supply and commercial manufacturing.
  • Financial terms of the acquisition remain confidential.

The big picture

Scinai's acquisition of Recipharm Israel and the strategic collaboration with Recipharm aim to address a common industry challenge: the friction and cost overruns when programs transition to global late-stage or commercial manufacturers. This move positions Scinai to offer an integrated, end-to-end development pathway, potentially attracting more biotech clients seeking seamless transitions from early development through commercialization. The deal underscores the trend of smaller CDMOs expanding their service offerings to compete with larger players.

What we're watching

Integration Success
How Scinai will integrate Recipharm Israel's operations and maintain operational continuity.
Client Transition
Whether the collaboration will successfully streamline transitions for clients from early-stage to late-stage manufacturing.
Competitive Positioning
The pace at which Scinai can differentiate itself among smaller CDMOs with this expanded offering.

Related topics

Acquisition